Barclays Reaffirms Equal Weight Rating for Certara (NASDAQ:CERT)

Certara (NASDAQ:CERT)‘s stock had its “equal weight” rating reiterated by Barclays in a research report issued to clients and investors on Friday, MarketBeat reports. They presently have a $8.00 price target on the stock. Barclays‘s price objective suggests a potential upside of 13.31% from the company’s current price.

CERT has been the subject of a number of other reports. BMO Capital Markets began coverage on shares of Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Rothschild & Co Redburn set a $10.00 price objective on Certara in a research note on Friday, November 21st. Wall Street Zen lowered Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. Finally, Stephens lowered their target price on Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.10.

Certara Trading Down 1.3%

Shares of Certara stock opened at $7.06 on Friday. The firm has a market cap of $1.12 billion, a PE ratio of -706.00 and a beta of 1.50. Certara has a 1 year low of $6.04 and a 1 year high of $15.38. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. The stock has a fifty day moving average price of $8.18 and a 200-day moving average price of $9.75.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. During the same period last year, the firm posted $0.15 earnings per share. Certara’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities research analysts anticipate that Certara will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC purchased a new stake in shares of Certara during the first quarter worth $259,000. Goldman Sachs Group Inc. grew its position in shares of Certara by 65.6% in the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after purchasing an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after purchasing an additional 35,954 shares during the period. Jane Street Group LLC lifted its holdings in Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, Bastion Asset Management Inc. bought a new position in Certara in the 2nd quarter worth about $2,554,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.